HDM1002
Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults
Huadong Medicine · Phase 2 · Status n/r · Enrollment 180
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| HDM1002 100mg BID | n/r | n/r | n/r | n/r |
| HDM1002 200mg BID | n/r | n/r | n/r | n/r |
| HDM1002 400mg QD | n/r | n/r | n/r | n/r |
| placebo | n/r | n/r | n/r | n/r |
Not shown
- HDM1002 100mg BID: endpoint not reported
- HDM1002 200mg BID: endpoint not reported
- HDM1002 400mg QD: endpoint not reported
- placebo: endpoint not reported